Efficacy of Low-dose Paclitaxel and Cisplatin in Patients with Advanced Non-Small Cell Lung Cancer.
- Author:
Byung Su KIM
1
;
Do Youn OH
;
Yo Han JOH
;
Do Yeun KIM
;
Jee Hyun KIM
;
Se Hoon LEE
;
Dae Ho LEE
;
Tae You KIM
;
Dae Seog HEO
;
Yung Jue BANG
;
Noe Kyeong KIM
Author Information
1. Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea. heo1013@plaza.snu.ac.kr
- Publication Type:Original Article
- Keywords:
Non-small cell lung cancer;
Chemotherapy;
Paclitaxel;
Cisplatin
- MeSH:
Adenocarcinoma;
Carcinoma;
Carcinoma, Large Cell;
Carcinoma, Non-Small-Cell Lung*;
Carcinoma, Squamous Cell;
Cisplatin*;
Drug Therapy;
Drug Therapy, Combination;
Fever;
Humans;
Hypersensitivity;
Mortality;
Neutropenia;
Paclitaxel*;
Thorax;
Vomiting
- From:Cancer Research and Treatment
2001;33(6):469-473
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: To evaluate the efficacy and toxicity of combination chemotherapy with low-dose paclitaxel and cisplatin in patients with advanced non-small cell lung cancer. MATERIALS AND METHODS: Chemotherapy-naive patients with unresectable, pathologically proven non-small cell lung cancer were eligible for inclusion in the study. Patients received paclitaxel (145 mg/m2 iv 3 hour D1) and cisplatin (60 mg/m2 iv D1) every 3 weeks. RESULTS: Forty-two patients were enrolled between February 2000 and February 2001. The median age was 53.5 years. Patients with adenocarcinoma numbered 29, squamous cell carcinoma 7, large cell carcinoma 3, and undifferentiated carcinoma 3. Seventeen patients had stage IIIB, 19 had stage IV disease and the remaining 6 displayed recurred disease after previous surgical resection. Four patients terminated treatment early because of hypersensitivity (1) and severe emesis (3). Of the 38 evaluable patients, 14 had PR and the response rate was 36.8%. Among partial responders, 6 patients received additional chest radiation. The median duration of response was 47.9 weeks and the median overall survival was 54.0 weeks. Of the total 176 courses, 14 were delayed, 22 required dose reduction, and grade 3~4 neutropenia occurred in 5.6% of courses. Only one episode of neutropenic fever developed and there were no treatment- related mortalities. Other toxicities were generally mild. CONCLUSION: The combination chemotherapy with low-dose paclitaxel and cisplatin was effective and tolerable in patients with advanced non-small cell lung cancer.
